Ultragenyx Pharmaceutical Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 108.83 million compared to USD 100.5 million a year ago. Net loss was USD 170.68 million compared to USD 163.97 million a year ago.

Basic loss per share from continuing operations was USD 2.03 compared to USD 2.33 a year ago.